“…Moreover, host factor-independent targeting of RV has also been reported in vitro using other small molecules with viroplasm/DLP disintegrating potency [ 306 ] and viral transcription inhibitory effects [ 307 ]. With the recent advances in technological refinement such as adopting human intestinal organoids as infection model [ 86 , 123 , 140 , 141 , 213 , 257–259 , 261 , 263 , 276 , 308 , 309 ] and using rotaviral reverse genetics [ 187 , 245 , 249 , 310–313 ], future research should be propelled toward unraveling novel mechanistic aspects of host–RV interactions, and assessing therapeutic potential of reported anti-RV small molecules (host-targeted, virus-targeted, or in potential synergistic combination) in clinical settings.…”